FDA Approves Venclexta for CLL With 17p Deletion

Share this content:
FDA Approves Venclexta for CLL With 17p Deletion
FDA Approves Venclexta for CLL With 17p Deletion

MONDAY, April 11, 2016 (HealthDay News) -- Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality, 17p deletion, in patients who have been treated with at least one prior therapy.

The newly approved drug targets the B-cell lymphoma 2 protein, which promotes cancer growth and often is overabundant in patients with CLL, the FDA said. Venclexta's effectiveness was tested in clinical studies involving 106 patients with CLL who have a 17p deletion and who had received at least one prior therapy. Eighty percent of trial participants showed a complete or partial remission, the agency said.

The drug's most common side effects included neutropenia, diarrhea, nausea, anemia, upper respiratory infection, thrombocytopenia, and fatigue. More serious complications included pneumonia, fever, and more severe anemia. Patients who take Venclexta should not be given live attenuated vaccines.

Venclexta is indicated for daily use following confirmation of 17p deletion via the FDA-approved companion diagnostic Vysis CLL FISH probe kit.

Venclexta is manufactured by Chicago-based AbbVie, and marketed by AbbVie and Genentech USA Inc. of South San Francisco, California. The Vysis CLL FISH probe kit is manufactured by Abbott Molecular in Des Plaines, Illinois.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

Congress Approves Bill Expanding Private Care for VA Patients

Congress Approves Bill Expanding Private Care for VA ...

New bill would open up access to private doctors for veterans

AAP Recommending Injectable Flu Shot for 2018-19 Flu Season

AAP Recommending Injectable Flu Shot for 2018-19 Flu ...

Children should receive injectable vaccine, which has been shown to be more consistently effective

Neurologists Identify New Type of Vertigo

Neurologists Identify New Type of Vertigo

Long-term prognosis favorable, with improvement of symptoms in more than half of patients